PDF(Pubmed)
Abstract：
UNASSIGNED: The current study shows that the incidence rate of triple-negative breast cancer accounts for 10-17% of invasive ductal carcinoma of the breast. There is no specific treatment target, the age of onset is relatively small, and the recurrence rate is relatively fast. The prognosis of breast cancer in different subtypes is the most unsatisfactory, with a 5-year survival rate of less than 15%. We report a typical case of metastatic advanced triple-negative breast cancer who responded well to apatinib mesylate after chemotherapy failure and achieved significant progression-free survival, which is relatively rare in triple-negative breast cancer with limited treatment means.
UNASSIGNED: A 55-year-old female was surgically diagnosed as triple-negative breast cancer on April 17, 2015. After surgery, she had lung metastasis after standard adjuvant chemotherapy and radiotherapy. After receiving the NX regimen (vinorelbine, capecitabine) for 8 cycles, she progressed. Because the patient refused later, she was adjusted to apatinib mesylate, and serious adverse reactions occurred during the treatment process. By adjusting the drug dose, and low-dose apatinib treatment, the lung lesions were close to complete response (CR), reaching a progression-free survival period of 45 months.
UNASSIGNED: Low-dose apatinib may be a promising anti-tumor drug for triple-negative breast cancer patients, which needs more samples to verify. This case may provide a reference for the treatment selection of triple-negative metastatic breast cancer in the future.
UNASSIGNED: A 55-year-old female was surgically diagnosed as triple-negative breast cancer on April 17, 2015. After surgery, she had lung metastasis after standard adjuvant chemotherapy and radiotherapy. After receiving the NX regimen (vinorelbine, capecitabine) for 8 cycles, she progressed. Because the patient refused later, she was adjusted to apatinib mesylate, and serious adverse reactions occurred during the treatment process. By adjusting the drug dose, and low-dose apatinib treatment, the lung lesions were close to complete response (CR), reaching a progression-free survival period of 45 months.
UNASSIGNED: Low-dose apatinib may be a promising anti-tumor drug for triple-negative breast cancer patients, which needs more samples to verify. This case may provide a reference for the treatment selection of triple-negative metastatic breast cancer in the future.
摘要：
■目前的研究表明，三阴性乳腺癌的发病率占乳腺浸润性导管癌的10-17％。没有具体的治疗目标，发病年龄相对较小，复发率相对较快。不同亚型乳腺癌的预后最不理想,5年生存率低于15%。我们报告了一个典型的转移性晚期三阴性乳腺癌病例，化疗失败后对甲磺酸阿帕替尼反应良好，并实现了显著的无进展生存期。这在治疗手段有限的三阴性乳腺癌中相对罕见。
■2015年4月17日，一名55岁女性被手术诊断为三阴性乳腺癌。手术后,标准辅助化疗和放疗后出现肺转移.在接受NX方案(长春瑞滨，卡培他滨)8个周期，她进步了。因为病人后来拒绝了，她调整了甲磺酸阿帕替尼,治疗过程中出现严重不良反应。通过调整药物剂量，和低剂量阿帕替尼治疗，肺部病变接近完全缓解（CR），达到45个月的无进展生存期。
■低剂量阿帕替尼对于三阴性乳腺癌患者可能是一种有前途的抗肿瘤药物，这需要更多的样本来验证。该病例可为今后三阴性转移性乳腺癌的治疗选择提供参考。
■2015年4月17日，一名55岁女性被手术诊断为三阴性乳腺癌。手术后,标准辅助化疗和放疗后出现肺转移.在接受NX方案(长春瑞滨，卡培他滨)8个周期，她进步了。因为病人后来拒绝了，她调整了甲磺酸阿帕替尼,治疗过程中出现严重不良反应。通过调整药物剂量，和低剂量阿帕替尼治疗，肺部病变接近完全缓解（CR），达到45个月的无进展生存期。
■低剂量阿帕替尼对于三阴性乳腺癌患者可能是一种有前途的抗肿瘤药物，这需要更多的样本来验证。该病例可为今后三阴性转移性乳腺癌的治疗选择提供参考。
